---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-042420"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:34:52.176208+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences Q2 net loss $12.8M; reports positive PCOS interim data

## Summary
- Net loss of $12.8M for Q2 2023 vs $11.9M for Q2 2022; six-month loss $25.6M.
- Cash, equivalents and investments of $120.5M; expected to fund operations into H1 2025.
- Collaboration revenue $2.2M from Kaken Pharmaceutical upfront payment recognition.
- Interim Phase 2 PCOS data (20 patients) suggests DHEAS reduction with tildacerfont; no serious AEs.
- CAHmelia-203 enrollment >75%; CAHmelia-204 nearing 75%; CAHptain cohort 3 screening underway.

## SEC filing metadata
- accession: 0000950170-23-042420
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017023042420/0000950170-23-042420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017023042420/sprb-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-042420
- JSON: https://secwatch.observer/filing/0000950170-23-042420.json
- Plain text: https://secwatch.observer/filing/0000950170-23-042420.txt

## Key facts
- Earnings Releases
  SPRUCE BIOSCIENCES, INC. reported second quarter ended June 30, 2023 results: revenue $2.2 million.
  - Period: second quarter ended June 30, 2023
  - Revenue: $2.2 million
  - Result: reported results
  source text: to fund operating and capital expenditures into the first half of 2025. • Collaboration Revenue: Collaboration revenue for the three and six months ended June 30, 2023 were $2.2 million and $4.1 million, respectively, compared to nil for the same periods in 2022. The increase in collaboration revenue reflects the partial recognition of the $15.0 million upfront
  evidence_url: https://www.sec.gov/Archives/edgar/data/1683553/000095017023042420/0000950170-23-042420-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.